Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
Best of 2024 Publications Digest
January 27, 2025
Did we cover your area of interest?
Nordic Bioscience digest of the Best of 2024 publication series
Welcome to our 2024 recap of our best publications – it was another successful and exciting year for Nordic Bioscience! Our scientific teams and collaborators have worked hard to further improve our technologies, aiming to facilitate better treatment options for patients in need. We have collected the best contributions of 2024 from our various focal points – and invite you to check out the articles according to your interest.
Cardiology
The aim of this study was to investigate type III collagen (COL III) turnover with the help of pharmacodynamic biomarkers in participants from the CANVAS Program.
The clinical outcomes explored in this study were hospitalization for heart failure, cardiovascular death and all-cause mortality.
Reflecting a shift in the dynamics of COL3 turnover after the treatment with canagliflozin, PRO-C3 and CTX-III are promising pharmacodynamic tools, and can be used to monitor the impact of the canagliflozin treatment and possibly other sodium-glucose co-transporter-2 inhibitors on tissue remodeling.
Dermatology
There is a need for identifying biomarkers related to PsA disease activity and flares to improve the management of PsA patients and decrease flares.
The serum biomarker panel of C3M, C4M, PRO-C3, PRO-C6, and CPa9-HNE reflecting synovitis, enthesitis, and neutrophil activity may serve as novel tool for quantitatively monitoring flares in PsA patients.
Such biomarkers may have valuable applications in the detection of disease, as well as the monitoring of health status.
Hepatology
As there is a need for non-invasive biomarkers that can accurately assess the disease severity and prognosis, we evaluated the ability of extracellular matrix remodeling markers to diagnose fibrosis stage and predict PSC-related fibrosis progression and clinical events.
We found that PRO-C3 and ELF may be utilized for staging and can act as prognostic markers in PSC, contributing to improving current screening and treatment of immune-mediated liver diseases.
Oncology
With increased stiffness and remodeling often driving tumor growth and metastasis, the extracellular matrix (ECM) plays a crucial role in cancer progression.
In our study, we developed the PRO-C12 ELISA, a non-invasive tool to monitor type XII collagen fragments in serum that is related to ECM stiffening and CAF activity, providing critical insights into tumor biology and metastasis risk.
By quantifying type XII collagen fragments in serum, clinicians and drug developers gain a powerful tool to non-invasively assess CAF-driven mechanisms.
Pulmonology
13 blood biomarkers representing extracellular matrix remodeling, epithelial stress, and thrombosis were measured by ELISA in the PROFILE study.
Our findings showed that blood biomarker clustering in pulmonary fibrosis identified three distinct blood biomarker signatures associated with lung function and prognosis, suggesting unique pulmonary fibrosis biomarker patterns.
These markers therefore support the presence of pulmonary fibrosis endotypes and have the potential to guide targeted therapy development.
Rheumatology
Despite the successful development of disease-modifying therapies, the heterogeneity of rheumatoid arthritis means that a significant proportion of patients respond poorly to treatment.
Our findings suggest that quantifying type VI collagen turnover could help predict which RA patients will benefit most from TCZ therapy, potentially leading to more personalized treatment approaches.
